6533b85dfe1ef96bd12be6ef
RESEARCH PRODUCT
Capturing colorectal cancer inter-tumor heterogeneity in patient-derived xenograft (PDX) models
Kieshen KalloeSander R. Van HooffHans M. RodermondRonald Van LeersumNathalie R. De VriesJan Paul MedemaMatilde TodaroTessa Van HerwaardenPramudita R. PrasetyantiJoan H. De JongPeter NürnbergGiorgio StassiMarek Franitzasubject
OncologyCancer Researchmedicine.medical_specialtyPartial representationColorectal cancerbusiness.industryTumor cellsmedicine.diseaseTumor heterogeneityTumor Subtype03 medical and health sciencesTherapeutic approach0302 clinical medicineOncology030220 oncology & carcinogenesisInternal medicinemedicineIn patientbusinessdescription
Patient-derived xenograft (PDX) models have become an important asset in translational cancer research. However, to provide a robust preclinical platform, PDXs need to accommodate the tumor heterogeneity that is observed in patients. Colorectal cancer (CRC) can be stratified into four consensus molecular subtypes (CMS) with distinct biological and clinical features. Surprisingly, using a set of CRC patients, we revealed the partial representation of tumor heterogeneity in PDX models. The epithelial subtypes, the largest subgroups of CRC subtype, were very ineffective in establishing PDXs, indicating the need for further optimization to develop an effective personalized therapeutic approach to CRC. Moreover, we showed that tumor cell proliferation was associated with successful PDX establishment and able to distinguish patient with poor clinical outcomes within CMS2 group.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2018-10-22 | International Journal of Cancer |